168 related articles for article (PubMed ID: 9456245)
1. Aromatase inhibitors as potential cancer chemopreventives.
Kelloff GJ; Lubet RA; Lieberman R; Eisenhauer K; Steele VE; Crowell JA; Hawk ET; Boone CW; Sigman CC
Cancer Epidemiol Biomarkers Prev; 1998 Jan; 7(1):65-78. PubMed ID: 9456245
[TBL] [Abstract][Full Text] [Related]
2. Molecular Action and Clinical Relevance of Aromatase Inhibitors.
Murphy MJ
Oncologist; 1998; 3(2):129-130. PubMed ID: 10388095
[TBL] [Abstract][Full Text] [Related]
3. Aromatase inhibitors: new endocrine treatment of breast cancer.
Brueggemeier RW
Semin Reprod Med; 2004 Feb; 22(1):31-43. PubMed ID: 15083379
[TBL] [Abstract][Full Text] [Related]
4. Aromatase inhibitors in breast cancer therapy.
Brueggemeier RW
Expert Rev Anticancer Ther; 2002 Apr; 2(2):181-91. PubMed ID: 12113240
[TBL] [Abstract][Full Text] [Related]
5. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
Berry J
Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
[TBL] [Abstract][Full Text] [Related]
6. Aromatase inhibitors and breast cancer.
Miller WR
Minerva Endocrinol; 2006 Mar; 31(1):27-46. PubMed ID: 16498362
[TBL] [Abstract][Full Text] [Related]
7. Prevention of hormone-related cancers: breast cancer.
Dunn BK; Wickerham DL; Ford LG
J Clin Oncol; 2005 Jan; 23(2):357-67. PubMed ID: 15637398
[TBL] [Abstract][Full Text] [Related]
8. Are all aromatase inhibitors the same? A review of the current evidence.
Jänicke F
Breast; 2004 Dec; 13 Suppl 1():S10-8. PubMed ID: 15585378
[TBL] [Abstract][Full Text] [Related]
9. Aromatase in the context of breast and endometrial cancer. A review.
Jongen VH; Hollema H; Van Der Zee AG; Heineman MJ
Minerva Endocrinol; 2006 Mar; 31(1):47-60. PubMed ID: 16498363
[TBL] [Abstract][Full Text] [Related]
10. In vivo and in vitro pharmacological studies of aminoglutethimide as an aromatase inhibitor.
Santen RJ; Santner SJ; Tilsen-Mallett N; Rosen HR; Samojlik E; Veldhuis JD
Cancer Res; 1982 Aug; 42(8 Suppl):3353s-3359s. PubMed ID: 7083200
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of aromatase as treatment of breast carcinoma in postmenopausal women.
Santen RJ; Boucher AE; Santner SJ; Henderson IC; Harvey H; Lipton A
J Lab Clin Med; 1987 Mar; 109(3):278-89. PubMed ID: 3546561
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive pharmacology and clinical efficacy of aromatase inhibitors.
Njar VC; Brodie AM
Drugs; 1999 Aug; 58(2):233-55. PubMed ID: 10473018
[TBL] [Abstract][Full Text] [Related]
13. Use of estrogen antagonists and aromatase inhibitors in breast cancer and hormonally sensitive tumors of the uterine body.
Gadducci A; Cosio S; Genazzani AR
Curr Opin Investig Drugs; 2004 Oct; 5(10):1031-44. PubMed ID: 15535424
[TBL] [Abstract][Full Text] [Related]
14. Induction of aromatase expression by aminoglutethimide, an aromatase inhibitor that is used to treat breast cancer in postmenopausal women.
Kao YC; Okubo T; Sun XZ; Chen S
Anticancer Res; 1999; 19(3A):2049-56. PubMed ID: 10470147
[TBL] [Abstract][Full Text] [Related]
15. Focus on anastrozole and breast cancer.
Mokbel K
Curr Med Res Opin; 2003; 19(8):683-8. PubMed ID: 14687437
[TBL] [Abstract][Full Text] [Related]
16. Endocrine therapy trials of aromatase inhibitors for breast cancer in the adjuvant and prevention settings.
Ingle JN
Clin Cancer Res; 2005 Jan; 11(2 Pt 2):900s-5s. PubMed ID: 15701884
[TBL] [Abstract][Full Text] [Related]
17. Peroxisome proliferator-activated receptor gamma ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implications for breast cancer therapy.
Rubin GL; Zhao Y; Kalus AM; Simpson ER
Cancer Res; 2000 Mar; 60(6):1604-8. PubMed ID: 10749129
[TBL] [Abstract][Full Text] [Related]
18. Anastrozole ('Arimidex') blocks oestrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancer.
Miller WR; Stuart M; Sahmoud T; Dixon JM
Br J Cancer; 2002 Oct; 87(9):950-5. PubMed ID: 12434282
[TBL] [Abstract][Full Text] [Related]
19. Effect of nomegestrol acetate on estrogen biosynthesis and transformation in MCF-7 and T47-D breast cancer cells.
Shields-Botella J; Chetrite G; Meschi S; Pasqualini JR
J Steroid Biochem Mol Biol; 2005 Jan; 93(1):1-13. PubMed ID: 15748827
[TBL] [Abstract][Full Text] [Related]
20. Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program.
Lane HA; Lebwohl D
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S18-25. PubMed ID: 16730273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
